公开(公告)号：US06423489B1

公开(公告)日：2002-07-23

申请号：US08452841

申请日：1995-05-30

申请人： Kevin P. Anderson ,  Ronnie C. Hanecak ,  Kazuya Hoshiko ,  Chikateru Nozaki ,  Tsukasa Nishihara ,  Hiroshi Nakatake ,  Fukusaburo Hamada ,  Tatsuo Eto ,  Shinichi Furukawa ,  Shoji Furusako ,  Thomas W. Bruice ,  Walter F. Lima

发明人： Kevin P. Anderson ,  Ronnie C. Hanecak ,  Kazuya Hoshiko ,  Chikateru Nozaki ,  Tsukasa Nishihara ,  Hiroshi Nakatake ,  Fukusaburo Hamada ,  Tatsuo Eto ,  Shinichi Furukawa ,  Shoji Furusako ,  Thomas W. Bruice ,  Walter F. Lima

IPC分类号： C12Q168

CPC分类号： C12N15/1131 ,  C07H21/00 ,  C07K14/005 ,  C12N2310/315 ,  C12N2310/33 ,  C12N2310/3521 ,  C12N2310/3527 ,  C12N2770/24222 ,  C12Q1/707

摘要： Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.

公开(公告)号：US06391542B1

公开(公告)日：2002-05-21

申请号：US08650093

申请日：1996-05-17

申请人： Kevin P. Anderson ,  Ronnie C. Hanecak ,  Kazuya Hoshiko ,  Chikateru Nozaki ,  Tsukasa Nishihara ,  Hiroshi Nakatake ,  Fukusaburo Hamada ,  Tatsuo Eto ,  Shinichi Furukawa ,  Shoji Furasako ,  Thomas W. Bruice ,  Walter F. Lima

发明人： Kevin P. Anderson ,  Ronnie C. Hanecak ,  Kazuya Hoshiko ,  Chikateru Nozaki ,  Tsukasa Nishihara ,  Hiroshi Nakatake ,  Fukusaburo Hamada ,  Tatsuo Eto ,  Shinichi Furukawa ,  Shoji Furasako ,  Thomas W. Bruice ,  Walter F. Lima

IPC分类号： C12Q168

CPC分类号： C12N15/1131 ,  C07H21/00 ,  C07K14/005 ,  C12N2310/315 ,  C12N2310/33 ,  C12N2310/3521 ,  C12N2310/3527 ,  C12N2770/24222 ,  C12Q1/707

摘要： Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.

摘要翻译： 提供反义寡核苷酸，其与至少一部分HCV RNA互补并可与其相互杂交，并能够抑制HCV RNA的功能。 可以施用这些寡核苷酸来体内或体外抑制丙型肝炎病毒的活性。 这些化合物可以预防性地或治疗性地用于降低与丙型肝炎病毒相关的疾病的严重性，以及HCV和HCV相关疾病的诊断和检测。 还公开了使用这些化合物的方法。

公开(公告)号：US06284458B1

公开(公告)日：2001-09-04

申请号：US08397220

申请日：1995-03-09

申请人： Kevin P. Anderson ,  Ronnie C. Hanecak ,  Kazuya Hoshiko ,  Chikateru Nozaki ,  Tsukasa Nishihara ,  Hiroshi Nakatake ,  Fukusaburo Hamada ,  Tatsuo Eto ,  Shinichi Furukawa

发明人： Kevin P. Anderson ,  Ronnie C. Hanecak ,  Kazuya Hoshiko ,  Chikateru Nozaki ,  Tsukasa Nishihara ,  Hiroshi Nakatake ,  Fukusaburo Hamada ,  Tatsuo Eto ,  Shinichi Furukawa

IPC分类号： C12Q168

CPC分类号： C12N15/1131 ,  C07H21/00 ,  C07K14/005 ,  C12N2310/315 ,  C12N2310/33 ,  C12N2310/3521 ,  C12N2310/3527 ,  C12N2770/24222 ,  C12Q1/707

摘要： Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.

公开(公告)号：US5059538A

公开(公告)日：1991-10-22

申请号：US896923

申请日：1986-08-15

申请人： Chikateru Nozaki ,  Hiroshi Nakatake ,  Yoichiro Kino ,  Tatsuo Eto ,  Keiichi Makizumi ,  Nobuya Ohtomo

发明人： Chikateru Nozaki ,  Hiroshi Nakatake ,  Yoichiro Kino ,  Tatsuo Eto ,  Keiichi Makizumi ,  Nobuya Ohtomo

IPC分类号： C12N15/09 ,  A61K39/00 ,  C07H21/04 ,  C07K14/035 ,  C12N15/00 ,  C12N15/38 ,  C12N15/81 ,  C12P21/02 ,  C12R1/19 ,  C12R1/865

CPC分类号： C12N15/81 ,  C07K14/005 ,  A61K39/00 ,  C12N2710/16622 ,  Y10S435/942

摘要： A novel recombinant plasmid inserted with a herpes simplex virus gene, which comprises a plasmid vector containing a yeast DNA sequence and an Escherichia coli DNA sequence and carrying a promoter region and a herpes simplex virus gN gene (HSVgB) gene) recombined thereto under control of the promoter, said HSVgB gene lacking an N-terminal portion of the gene including a signal sequence-encoding region and optionally further lacking the region downstream therefrom, such as a gB gene lacking a DNA sequence encoding the N-terminal 30 amino acids, and a gB gene lacking a DNA sequence encoding the N-terminal 83 amino acids. The recombinant plasmid is useful for the production of transformed yeast, which is useful for the production of HSVgB proteins suitable for producing HSV vaccine and diagnostic reagents for herpes simplex virus infections.

摘要翻译： 一种插入单纯疱疹病毒基因的新型重组质粒，其包含含有酵母DNA序列和大肠杆菌DNA序列并携带启动子区域和单纯疱疹病毒gN基因（HSVgB）基因）的质粒载体， 启动子，所述HSVgB基因缺失包含信号序列编码区的基因的N末端部分，并且任选地进一步缺少其下游区域，例如缺乏编码N末端30个氨基酸的DNA序列的gB基因，以及 缺乏编码N-末端83个氨基酸的DNA序列的gB基因。 重组质粒可用于生产转化酵母，其可用于生产适用于生产HSV疫苗的HSVgB蛋白和用于单纯疱疹病毒感染的诊断试剂。